Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients

Alberto Esteban-Fernández, Silvia López-Fernández, Francisco J. Pastor-Pérez, José Ángel Pérez-Rivera, Juan Luis Bonilla-Palomas, Marta Cobo-Marcos, José Manuel García-Pinilla, Luis Almenar-Bonet, Paula Fluviá-Brugués, Francisco J. Bermúdez-Jiménez, Cristina Goena-Vives, Andrea López-López, Inés Góm · 2025

Read Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients by Alberto Esteban-Fernández, Silvia López-Fernández, Francisco J. Pastor-Pérez, José Ángel Pérez-Rivera, Juan Luis Bonilla-Palomas, Marta Cobo-Marcos, José Manuel García-Pinilla, Luis Almenar-Bonet, Paula Fluviá-Brugués, Francisco J. Bermúdez-Jiménez, Cristina Goena-Vives, Andrea López-López, Inés Góm (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750671.txt.

Description

Alberto Esteban-Fernández and co-authors ask whether a newer diabetes drug should start immediately when heart failure is first diagnosed, in a 2025 study. Modern treatment for a weakened heart combines four drug families, and the sooner all four are aboard, the better patients do. One family, the SGLT2 inhibitors, began as diabetes drugs. A Spanish registry enrolled newly diagnosed patients across many hospitals in 2021 and 2022.

This analysis split patients by whether their first drug combination already included an SGLT2 inhibitor. Over six months the team tracked symptoms, heart scans, blood tests, hospitalisations, and emergency visits, plus how many patients reached full four-drug therapy. The comparison tests whether leading with this family speeds the build-up of complete treatment and cuts early setbacks, evidence doctors can use when writing the first prescription.

Catalog record

CREATORAlberto Esteban-Fernández, Silvia López-Fernández, Francisco J. Pastor-Pérez, José Ángel Pérez-Rivera, Juan Luis Bonilla-Palomas, Marta Cobo-Marcos, José Manuel García-Pinilla, Luis Almenar-Bonet, Paula Fluviá-Brugués, Francisco J. Bermúdez-Jiménez, Cristina Goena-Vives, Andrea López-López, Inés Góm
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12750671

Browse the full library · About the Tower of Babel